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Pancreatic β-cells regulate glucose metabolism by secreting insulin, which in turn
stimulates the utilization or storage of the sugar by peripheral tissues. Insulin insufficiency
and a prolonged period of insulin resistance are usually the core components of type
2 diabetes (T2D). Although, decreased insulin levels in T2D have long been attributed
to a decrease in β-cell function and/or mass, this model has recently been refined with
the recognition that a loss of β-cell “identity” and dedifferentiation also contribute to
the decline in insulin production. MicroRNAs (miRNAs) are key regulatory molecules
that display tissue-specific expression patterns and maintain the differentiated state of
somatic cells. During the past few years, great strides have been made in understanding
how miRNA circuits impact β-cell identity. Here, we review current knowledge on the
role of miRNAs in regulating the acquisition of the β-cell fate during development
and in maintaining mature β-cell identity and function during stress situations such as
obesity, pregnancy, aging, or diabetes. We also discuss how miRNA function could be
harnessed to improve our ability to generate β-cells for replacement therapy for T2D.
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BACKGROUND
Pancreatic β-cells are responsible for insulin release and thus are essential for normal blood
glucose homeostasis. Thanks to an unusual metabolic configuration (Rutter, 2001, 2004; Rutter
et al., 2015), β-cells act as nutrient sensors by coupling oxidative glucose metabolism to insulin
secretion, delivering an appropriate quantity of the hormone into the bloodstream at any given
time. When metabolized by the β-cell, glucose promotes an increase in intracellular ATP/ADP
ratio that induces the closure of ATP-sensitive K+ channels (KATP) (Ashcroft and Rorsman, 2013)
which in turn leads to the depolarization of the plasma membrane and the opening of voltage-
gated Ca2+ channels. The resultant increase in intracellular free Ca2+ triggers both the exocytotic
release of insulin from secretory granules and reinforces the response by stimulating further ATP
production by mitochondria (Rutter et al., 2015). Other KATP-independent mechanisms (Henquin,
2009), which are still incompletely understood but may include the inhibition of AMP-activated
kinase (AMPK) and the action of fatty acid derivatives, potentiate the above signaling mechanism
(da Silva Xavier et al., 2003; Prentki et al., 2013).
During the development of T2D, peripheral insulin resistance leads to hyperglycemia and
initially triggers a compensatory response from the β-cells to release more insulin (Nolan et al.,
2006). Frank diabetes presents when β-cells are incapable of compensating for insulin resistance,
and this is associated with some loss of β-cell mass (Butler et al., 2003; Rahier et al., 2008),
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whose extent is debated (25–50%), compounded by impaired
glucose-stimulated insulin secretion from the remaining β-cells
(Meier and Bonadonna, 2013). Importantly, the first phase of
insulin secretion is usually lost when fasting blood glucose levels
are only slightly raised (∼6 mmol/L), suggesting that β-cell
dysfunction is an early event in disease progression (Kahn et al.,
2009).
Loss of β-cell identity (i.e., de-differentiation or trans-
differentiation) has recently been suggested to be an important
contributor to both the apparent loss of β-cell mass which may be
the result of a failure to detect remaining β-cells in which insulin
levels have fallen below threshold levels (Marselli et al., 2014)
and to impaired function (Del Guerra et al., 2005). The latter
phenomenon was first described in hyperglycemic and Zucker
Diabetic Fatty rats (Tokuyama et al., 1995; Jonas et al., 1999), and
is characterized by increased expression of normally repressed
genes, such as hexokinase (HKI-III), and decreased levels of genes
important for β-cell secretory function (e.g., Glut2/Slc2a2) as well
as key transcription factors such as Pdx1. Moreover, in the mouse,
genetic ablation of FoxO1 caused β-cells to de-differentiate
into progenitor-like cells and even α-cell-like cells following
physiologic stress associated with insulin resistance (multiple
pregnancies or aging) (Talchai et al., 2012). Likewise, Nkx6.1 and
Pdx1-deficient β-cells acquired the molecular characteristics of
δ-cells and α-cells, respectively (Schaffer et al., 2013; Taylor et al.,
2013; Gao et al., 2014). In certain cases, dedifferentiated, or so-
called “empty” (i.e., depleted in dense core insulin-containing
granules) β-cells, express markers solely found in endocrine
progenitor cells (Talchai et al., 2012; Puri et al., 2013; Wang et al.,
2014) presumably reflecting plasticity to allow reprogramming
toward an alternate endocrine identity (Talchai et al., 2012; Taylor
et al., 2013; White et al., 2013). Most recently, Spijker et al.
(2015) presented evidence that loss of β-cell identity occurs in
T2D in humans and primates, although its contribution to the
development of diabetes remains contested (Butler and Dhawan,
2015; Butler et al., 2016; Md Moin et al., 2016; Wang Y.J. et al.,
2016) with little evidence from studies of the islet transcriptome
from subjects with T2D of increases in progenitor markers
(Fadista et al., 2014).
β-cell identity is normally maintained at multiple levels,
including through the action of transcriptional activators and/or
repressors, epigenetic mechanisms (such as DNA methylation or
histone modifications) and non-coding RNAs. De-regulation of
any or all of these in the β-cell might thus be associated with
the development of diabetes (McKinnon and Docherty, 2001;
Avrahami and Kaestner, 2012; Gilbert and Liu, 2012; Pullen and
Rutter, 2014; Dayeh and Ling, 2015).
The majority of the genome (∼98%) is transcribed to
produce transcripts lacking protein-coding potential, including
microRNAs (miRNAs). MiRNAs are 21–22 nucleotide-long
molecules that silence gene expression post-transcriptionally.
More than 2,000 miRNAs have been identified so far in humans
which regulate virtually every aspect of cell biology, including
development, proliferation, differentiation or metabolism (Sun
and Lai, 2013). It is therefore not surprising that disruption of
miRNA function contributes to many human diseases, including
cardiovascular disorders, cancer and neurological dysfunction
(Small and Olson, 2011; Mendell and Olson, 2012; Emde and
Hornstein, 2014).
Micro RNAs are transcribed as longer precursors (pri-
miRNAs), generally by polymerase II (Lee et al., 2004). Thus,
the expression of a large subset of mammalian miRNAs may be
transcriptionally linked to the expression of other genes, allowing
for coordinate regulation of miRNA and protein expression
(Schanen and Li, 2011). Pri-miRNAs are first processed in the
nucleus by DROSHA and, in mammals, DGCR8, into a ∼70 nt
hairpin, known as pre-miRNA. The pre-miRNA is then exported
to the cytoplasm where it is further processed by DICER into a
small (∼20 nt) RNA duplex. In general, one of the strands (known
as the guide) will be incorporated within an Argonaute (Ago)
protein into a miRNA-induced silencing complex (miRISC)
while the other one (passenger strand) is released and degraded
(Finnegan and Pasquinelli, 2013).
Most metazoan miRNAs direct miRISC to the target mRNAs
by interacting with sites of imperfect complementarity to
induce their degradation and/or inhibit translation, resulting
in repression of its expression (Pasquinelli, 2012). In general,
the most important region for target recognition comprises the
nucleotides 2–8 of the miRNA- known as the “seed” region-
and binding sites located in the 3′ UTR of the cognate mRNAs
are more common (Bartel, 2009). The capacity of miRNAs to
target several transcripts simultaneously, while a given transcript
can be concomitantly targeted by several different miRNAs,
suggests an ability to build a complex regulatory network for fine-
tuning gene expression (Gurtan and Sharp, 2013). Thus, miRNAs
may contribute to maintain cell function in spite of internal or
external perturbations and have recently emerged as reinforcers
of developmental transitions and cellular identities (Ebert and
Sharp, 2012). In the adult, miRNAs contribute to the maintenance
of cell identity in a variety of cell types (Li and Jin, 2010; Xin et al.,
2013) and to changes in cell fate in cancer (Berdasco and Esteller,
2010). MiRNAs might suppress neuronal genes during endocrine
cell maturation (Kanji et al., 2013) and silence transcriptional
repressors in adult β-cells (Melkman-Zehavi et al., 2011).
In this review, we discuss firstly the role miRNAs play in the
acquisition and maintenance of β-cell identity. We then go on to
describe how dysregulation of miRNA networks in response to
metabolic stress or cellular insults might contribute to the loss of
β-cell identity and to the development of T2D.
MiRNAs AND THE ACQUISITION OF
β-CELL IDENTITY
The past few years have provided a substantial amount of
information on the morphological changes occurring during
early pancreas formation in the mouse (Jorgensen et al.,
2007) and humans (Pan and Brissova, 2014; Jennings et al.,
2015). In mice, pancreas development is initiated by two
evaginations of the foregut endoderm at embryonic day 8.5
(E8.5). These so-called pancreatic dorsal and ventral buds arise
from thickening of the pancreatic epithelium that undergoes
branching morphogenesis and eventually fuse to form a single
organ later in embryogenesis. Pancreatic progenitor cells are
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defined by the expression of several transcriptional regulators
including Tcf2, HNF6, Foxa2, Hb9, Pdx1, Ptf1a, Nkx2.2, Nkx6.1,
Sox4, Gata6, Gata4, and Sox9 (Maestro et al., 2003; Cano
et al., 2014) which will differentiate into three different cell
types composing the pancreas: endocrine, exocrine, and ductal
cells. The differentiation of the pancreatic endocrine lineage
including insulin-producing β-cells is triggered by the transient
activation of neurogenin3 (Ngn3), a basic helix-loop-helix
(bHLH) transcription factors enhancing the expression of lineage
committed transcriptional regulators such as Rfx6 (Smith et al.,
2010; Soyer et al., 2010). Although Ngn3 expression is gradually
lost by E15.5, its downstream transcriptional activators enable
the terminal differentiation of pancreatic β-cells into mature
insulin-producing cells.
Analysis of conditional Dicer1 null mice has revealed
the importance of miRNAs in the regulation of pancreatic
endocrine cell differentiation. Deletion of Dicer1 selectively in
the developing pancreas (e8.5) using a Pdx1-Cre deleter strain
produced a deficiency of β-cells attributed to a marked decreased
in the number of Ngn3+ endocrine progenitor cells (Lynn et al.,
2007). This result indicated an important role of miRNAs in
the specification of progenitors into the endocrine lineage of
the pancreas. In contrast, Kanji et al. (2013) showed that mice
born with specific deletion of Dicer1 in Ngn3+ progenitors are
morphologically indistinguishable from controls and present no
alteration in endocrine cell mass. However, a few weeks after birth
the latter animals develop a striking decrease in endocrine cell
mass, which is associated with decreased insulin secretion and the
appearance of hyperglycemia. A further fascinating observation
is the de-repression of several neuronal genes in neonatal
Dicer1Ngn3−cre islets including Rest1, tyrosine hydroxylase (Th),
Phox2a and Phox2b. This indicates that Dicer1 is dispensable for
the specification of endocrine progenitors as hormone-producing
cells but highlights a crucial role of miRNAs in maintaining β-cell
identity by repressing a neuronal gene program (Kanji et al.,
2013). Kalis et al. (2011) reported that conditional inactivation
of Dicer1 in differentiated β-cells using Rip-Cre transgenic mice
doesn’t affects β-cell mass in newborn mice. However, at 12-week
of age, these mutant mice gradually developed hyperglycemia
from 12 weeks, glucose intolerance and full-blown diabetes
mellitus, which is attributed to impaired insulin secretion and loss
of β-cell mass (Kalis et al., 2011; Mandelbaum et al., 2012).
Taken together, the above loss-of-function studies
demonstrate a role for Dicer1 and miRNAs in the early stages of
pancreatic cell lineage differentiation (Figure 1). Nonetheless,
they provide little information as to the role of specific miRNAs
in the differentiation of β-cells. Initial small RNA cloning studies
by Poy et al. (2004) revealed the existence of a diverse miRNA
transcriptome in the MIN6 insulinoma cell line that included
the highly expressed miR-375 (Pullen et al., 2011). Many other
groups have subsequently confirmed high expression of miR-375
in adult mouse (Landgraf et al., 2007; Avnit-Sagi et al., 2009; Poy
et al., 2009) and human (van de Bunt et al., 2013) islets as well
as purified β-cells (Klein et al., 2013). Other profiling studies
performed in the developing pancreas identified a set of miRNA
whose expression was altered as the differentiation of pancreatic
endocrine cells proceeds. In humans these include, amongst
others, miR-7, -9, -15a/15b/16/195, -124a, -195, -218, -195, -375,
-376a, -503, and -541 (Correa-Medina et al., 2009; Joglekar et al.,
2009a; Sun and Lai, 2013). Conversely, e14.5 mouse pancreas
shows high levels of let-7a, miR-136, -214, -375, -503, -541 (Lynn
et al., 2007) whereas rat e20 pancreas hast high levels of miR-21,
-23a, -29a, -125b, -376b, and -451 (Larsen et al., 2011).
Although, little genetic evidence exists demonstrating
a role for the above specific miRNAs in pancreas genesis,
they may regulate the acquisition of β-cell identity during
early embryogenesis. In fact, miR-375, is also expressed in
endodermal progenitor cells. Moreover, inhibition of miR-
375 by morpholino oligonucleotides inhibits pancreatic islet
development in Xenopus laevis (Kloosterman et al., 2007).
The importance of miR-375 in regulating β-cell mass is also
conserved in mice where global genetic inactivation of miR-
375 results in decreased β-cell mass and diabetes (Poy et al.,
2009; Latreille et al., 2015). MiR-375 expression levels also
increased during pancreas development in humans (Joglekar
et al., 2009a). Interestingly, the miR-375 promoter contains
highly conserved binding sites for the transcriptional regulators
hepatocyte nuclear factor 6 (HNF6) and Insulinoma-assoicated-1
(INSM1), two critical components of the transcriptional cascade
regulating Ngn3-dependent endocrine progenitor differentiation
(Jacquemin et al., 2000; Avnit-Sagi et al., 2009, 2012; Zhang
et al., 2009). PDX1, NGN3 and NEUROD1 binding sites are
also found in enhancer regions required for full transcriptional
activity of the miR-375 gene (Keller et al., 2007; Avnit-Sagi
et al., 2009). Interestingly, several predicted mRNA targets
of miR-375 such as Gata6, Hnf1α, and Pax6 play important
roles during the specification of pancreatic progenitors and
terminal maturation of endocrine cells indicating that a miR-
375 circuit directs appropriate β-cell development through
temporal controls of β-cell transcription factor expression.
Characterization of conditional mice with stage-specific
inactivation of miR-375 in pancreatic and endocrine progenitors
should help clarify the physiological role of miR-375 in β-cell
differentiation.
Kredo-Russo et al. (2012) also provided evidence for a role of
miR-7 during pancreas development. Overexpression of miR-7 in
pancreatic progenitors impaired differentiation of α- and β-cells
and correlated with a repression of Pax6 gene expression. These
mutant mice displayed a similar phenotype to Pax6 knockout
animals. A comprehensive review of the function of miR-7 in
regulating the identity of β-cells is presented below in the Case
Study (see Box 1 and Figure 2).
Fu et al. (2013) revealed that overexpression of miR-26a in
mice increased the number of Ngn3+ endocrine progenitors
and promoted their differentiation to into β-cells, findings
that could be reproduced in vitro in sorted CD133+/Sox9+
progenitor-like cells. Several other groups reported that miRNAs
inhibit the expression of multiple transcription factors driving
β-cell differentiation. For example, miR-124a is abundant in e18
pancreas and represses Foxa2 expression (Baroukh et al., 2007;
Jing et al., 2014) suggesting that it may regulate the acquisition of
the β-cell identity during development. MiR-124a also represses
Neurod1 in both MIN6 cells (Sebastiani et al., 2015) and neurons
(Cheng et al., 2009; Liu et al., 2011). No genetic evidence
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FIGURE 1 | Impact of Dicer depletion on β-cell maturation and maintenance. Progenitors and mature β-cells are represented in different colors. The deleter
strains are indicated in blue and contain references to the corresponding papers: (1) Lynn et al. (2007); (2) Kanji et al. (2013); (3) Mandelbaum et al. (2012); (4) Kanji
et al. (2013); (5) Melkman-Zehavi et al. (2011); (6) Martinez-Sanchez et al. (2015). The black arrows mark the moment at which deletion occurs. Red cells represent
defective cells and the biological pathways/functions affected are indicated in red. hPSC, human pluripotent stem cell.
for a role of this miRNA in the differentiation of pancreatic
progenitor is available yet, but the relevance of miR-124a to the
regulation of cellular identity is demonstrated by the suppression
of non-neuronal genes by miR-124a in neuronal cells (Conaco
et al., 2006). Interestingly, miR-124a expression is induced in
islets from diabetic patients (Sebastiani et al., 2015) and single
nucleotide polymorphisms (SNPs) in miR-124a gene have been
identified in T2D islets (Ciccacci et al., 2013; Li Y. et al., 2015).
Although expressed in low levels in adult islets, miR-124a is
involved in the regulation of ATP-sensitive K+ channels, thus
influencing glucose-stimulated Ca2+ dynamics (Baroukh et al.,
2007).
Joglekar et al. (2007) also discovered that miR-15a and
15b were induced in regenerating, compared to developing,
pancreas and found these to repress Ngn3 via a post-
transcriptional mechanism. By performing both gain- and loss-
of-function experiments in mice, the above authors found that
overexpression of miR15a/15b in pancreatic buds decreased Ngn3
levels and reduced the number of α- and β-cells, whereas blocking
miR-15 increased Ngn3 levels after partial pancreatotectomy
in mice led to higher levels of Nkx2-2 and NeuroD1, two of
its downstream targets. Rfx6, another Ngn3-dependent gene
in endocrine cells, is under tight regulation by two glucose-
regulated miRNAs, miR-30d and let-7e (Liao et al., 2013). Others
have shown that miR-19b represses insulin gene transcription
following engagement of its mRNA target NeuroD1 (Zhang
et al., 2011). Nevertheless, a role for miR-19b, miR-30d, and
let-7e during β-cell development remains to be demonstrated.
Together, these findings highlight a complex interplay between
miRNAs and transcription factors in β-cells. Future work in
mice should help clarify how these interconnecting networks
contribute to differentiation of β-cells in whole animals.
ROLE OF miRNAs IN MAINTAINING
MATURE β-CELL IDENTITY
Using genetic mouse models of DICER depletion, we and
others have demonstrated that miRNAs are essential for the
maintenance of mature β-cell identity, function, and survival
(Figure 1). Thus, Melkman-Zehavi et al. (2011) were the first
to examine the effects of disrupted DICER function in adult
β-cells, using an inducible conditional RIP-CreER deleter strain.
As early as 3 weeks after Dicer deletion, the null mice presented
with marked hyperglycemia and glucose intolerance, mainly
due to a severe reduction in β-cell insulin gene expression.
Using a similar model and an inducible Pdx1-CreER deleter
strain (Martinez-Sanchez et al., 2015) we proved that Dicer
deletion eventually results in a strong decrease in β-cell mass.
Most importantly, our studies demonstrated that the β-cell
capacity to secrete insulin in response to a glucose challenge
in miRNA-null islets was significantly impaired, a defect that
preceded any loss in β-cell mass or insulin content. These
defects, occurred concurrently with the up-regulation of β-cell
“disallowed” genes, might contribute to loss of β-cell identity
(see MiRNAs and Disallowed Genes). However, the expression
of β-cell signature genes (e.g., Pdx1, Nkx6.1, Nkx2.2, NeuroD1, or
MafA) was not altered in islets from either mouse model. Notably,
Melkman-Zehavi et al. (2011) observed an up-regulation of the
transcriptional repressors Sox6 and Bhlhe22, associated with
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BOX 1 | MiR-7 as a regulator of β-cell identity.
MiR-7 gene family. MiR-7 is amongst the most highly conserved miRNAs during evolution. In mice, three independent genomic loci encode miR-7: miR-7-al,
miR-7-a2, and miR-7b (miR-7-1, miR-7-2, and miR-7b in humans). Unlike the intergenic miR-7a-2 and miR-7b genes, miR-7a-1 is found on chromosome 13 inside
an intron linking exon 15 and 16 of the HNRNPK gene. In humans, all three mature miRNAs have identical nucleotide sequence whereas in mice and rats, miR-7b
is distinct from the other two family members by a single substitution following the regulatory seed sequence mediating mRNA target selectivity. MiR-7 is a typical
neuroendocrine miRNA expressed at high levels in pancreatic islets, pituitary, hypothalamus, and adrenals in mice and humans (Landgraf et al., 2007). Whereas little
is known about the regulation of miR-7 gene transcription in these tissues, evidence for regulation of the processing of the primary transcript by RNA binding proteins
has been demonstrated in various cell types (Lebedeva et al., 2011; Choudhury et al., 2013; Wang et al., 2013b). More recently, the ciRS-7 circular RNA, containing
more than 70 highly conserved miR-7 binding sites and able to act as a sponge which titrates miR-7 activity, has been detected at high levels in brain (Hansen et al.,
2013; Memczak et al., 2013). Interestingly, a recent report indicates that ciRS-7 is also expressed in pancreatic β-cells and regulates insulin gene transcription and
secretion though change in miR-7 activity (Xu et al., 2015).
Role of miR-7 in pancreas development. Earlier studies (Wienholds et al., 2005) demonstrated that miR-7 is present in the developing pancreas in Xenopus laevis.
In mammals, in situ hybridization revealed that miR-7 is predominantly expressed in insulin-, glucagon-, and somatostatin-producing cells of the developing and adult
pancreas (Correa-Medina et al., 2009; Joglekar et al., 2009a; Kredo-Russo et al., 2012; Nieto et al., 2012). Furthermore, dynamic changes in miR-7 levels were found
during pancreatic progenitor differentiation in mice (Nieto et al., 2012) and humans (Joglekar et al., 2009a). Similarly, miR-7 levels increase in human embryonic stem
cells differentiated into insulin-producing cell in vitro, suggesting a role for the miRNA in the regulation of endocrine cell differentiation during development (Liao et al.,
2013; Wei et al., 2013). Kredo-Russo et al. (2012) engineered conditional mice with a miR-7 gene targeted into the Rosa26 locus, which upon crossing with Pdx1-Cre
mice allows for the overexpression of miR-7 in pancreatic progenitors. E15.5 mutant embryos displayed a decrease in proinsulin and proglucagon mRNAs. More
investigation will be required to determine whether miR-7 affects endocrine lineage choice or the hormone contents in these cells. Interestingly, miR-7 expression is
strikingly down-regulated in E14.5 Ngn3 knockout embryos (Kredo-Russo et al., 2012), suggesting that NGN3 drives endocrine cell differentiation through modulation
of miR-7 expression.
Function of miR-7 in adult mouse and humans β-cells. MiR-7a-1 and miR-7a-2 conditional knockout mice were generated upon crossing floxed mice to RIP-Cre
transgenic mice to achieve selective inactivation in the β-cell (Latreille et al., 2014). These investigations revealed improved glucose tolerance in miR-7a2 β-cell-specific
knockout mice, which was associated with increased glucose-stimulated insulin secretion, findings recently confirmed by others (Xu et al., 2015). Electrophysiological
measurements of capacitance changes revealed that miR-7 acts on the distal step of insulin granule fusion with the plasma membrane. Gene profiling analyses
revealed that miR-7a represses several mRNAs encoding regulators of exocytosis and cytoskeleton reorganization including synuclein-a (Snca; Burre et al., 2010;
Latreille et al., 2014). In contrast, mice overexpressing miR-7a-2 in β-cells developed pronounced diabetes from 4 weeks of age and this was associated with
a decrease in circulating insulin levels due to a secretory deficit of β-cells (Latreille et al., 2014). Mutant mice also present with a striking down-regulation in the
expression of insulin and of β-cell transcription factors including Pdxl, Nkx6.1, MafA, Neurodl, and Pax6. Given that Pax6 is directly repressed by miR-7 in β-cells
(Kredo-Russo et al., 2012; Latreille et al., 2014) and Pax6 inactivation lowers insulin mRNA levels (Ahmad et al., 2015), the above suggests a pivotal role for the
miR-7/Pax6 axis in triggering loss of β-cell identity in T2D. By regulating both the biosynthesis and secretion of insulin through Pax6 and Snca, respectively, miR-7
thus represents a node in a complex gene circuit regulating both the insulin transcription (i.e., β-cell identity) and secretion (Figure 2A). Using dissociated adult primary
β-cells, Wang et al. (2013a) demonstrated that anti-miR-7 oligonucleotide promotes β-cell replication in vitro by derepressing components of the mTOR signaling
pathways (Figure 2A). In contrast, loss- of function studies in mice failed to reveal a role for miR-7 in regulating the β-cell proliferation in vivo (Latreille et al., 2014).
This could be explained by the methodology used or/and by the residual miR-7b levels found in characterized miR-7 knockout mice, which could mask an effect on
β-cell proliferation. Further studies are warranted to clarify this discrepancy.
Modulation of miR-7 expression by metabolic stress. Given the physiological importance of miR-7 in regulating insulin exocytosis in β-cells, profiling of miR-7
expression was performed in mouse models of obesity and diabetes. miR-7a levels are decreased in islets from insulin resistant and obese mice (e.g., high fat feeding
and ob/ob mice) that maintain euglycemia through a compensatory increase in insulin secretion. In contrast, islets from decompensating, hypoinsulinemic and diabetic
db/db mice present increased expression of miR-7a, indicating that miR-7 gene induction accompanies pancreatic β-cell failure in diabetes. This further supports
findings from Esguerra et al. (2011) showing increased levels of miR-7 in islets from non-obese GK diabetic rats. These observations were confirmed in healthy human
islets transplanted under the kidney capsule of mice fed a high fat diet (Latreille et al., 2014). In the latter setting, miR-7a expression is down-regulated in transplants a
few weeks after exposure to high fat diet, but gradually increases as metabolic stress impairs the ability of β-cells to secrete sufficient insulin to counteract peripheral
insulin resistance (Latreille et al., 2014). Similarly, islets from obese pre-diabetic patients present with a ∼50% decrease in miR-7 levels (Latreille et al., 2014). On the
other hand, quantification of miR-7 gene expression in islets from mildly diabetic patients (HbAlc 6.6 mmol/mol) surprisingly revealed lower miR-7 levels compared to
controls, thus suggesting that the human response to metabolic stress in islets may differ from mice or alternatively that treatment of those patients may have allowed
compensatory n-cell function to obesity and insulin resistance. Together, this reveals a dynamic remodeling of miR-7 expression during the natural progression of
T2D, which contributes to the functional adaptation of β-cells to metabolic stress (Figure 2B).
Open questions. These observations raise several questions on the physiological role of miR-7 in the pancreas. First, what is the precise biological function of miR-7
in healthy β-cells? One possibility is that it contributes toward buffering β-cell gene networks to provide functional robustness (Siciliano et al., 2013). Another possibility,
although less attractive, is that miR-7 may mediate the functional adaptation of β-cells following a rapid elevation in glycaemia to prevent the over-secretion of insulin
and hypoglycaemia. Due to the relatively high stability of miRNAs, it is unconceivable that prompt (sec–min.) fluctuation in insulin secretion could be explained by
a change in miRNA expression. Second, is miR-7 induction the cause or simply yet another gene associated with β-cell failure and dedifferentiation in T2D? Third,
what are the mechanisms underlying miR-7-induced dedifferentiation? Is this solely mediated by the single repression of Pax6 or caused by a combinatorial effect on
multiple mRNA encoding for products maintaining the identity of β-cells? More investigation will be required to provide answers to these. This challenging endeavor
will need to be fulfilled as it could provide innovating therapeutic opportunities leading to the development of anti-miR-7 agents to treating β-cell failure in T2D.
multipotency. Although the latter regulators are not ubiquitously
expressed and do not, therefore, meet the criteria to be
members of the “disallowed” gene family their expression is
typically low in β-cells allowing efficient insulin transcription.
Therefore, the up-regulation of these genes as a consequence
of miRNA depletion might also contribute to the loss of β-cell
identity.
As mentioned earlier, depletion of DICER in endocrine
progenitors led to up-regulation of neuronal genes in early post-
natal islets (Kanji et al., 2013). An increase in neuronal gene
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expression has also been observed in islets from mice with β-cell-
specific deletion of LKB1 or AMPK (Kone et al., 2014) and
contributes to the loss of β-cell identity, and possibly function,
observed in these models. An up-regulation of neuronal genes
following miRNA depletion in mature β-cells similarly occur and
contribute to the failure of β-cell function in the latter setting.
Nevertheless, this is an exciting possibility that remains to be
explored.
Out of the 100s of miRNAs expressed in mature β-cells the
function of only a small proportion has been deciphered so
far. Specific miRNAs affect insulin production (Melkman-Zehavi
et al., 2011; Zhang et al., 2011; Nieto et al., 2012; Setyowati
Karolina et al., 2013; Xu et al., 2015), insulin exocytosis (Plaisance
et al., 2006; Lovis et al., 2008a), growth (Tattikota et al., 2014),
or apoptosis (Lovis et al., 2008b; Ruan et al., 2011). Additionally,
to the best of our knowledge, the function of only four miRNAs
(miR-375, miR-7a, miR-184, and the miR-200 family) has been
addressed in vivo in the β-cell using mouse genetic studies (Poy
et al., 2009; Latreille et al., 2014; Tattikota et al., 2014; Belgardt
et al., 2015). This work has very recently been reviewed elsewhere
(Filios and Shalev, 2015; Guay and Regazzi, 2016) and is not
discussed here. Rather, we will focus on (1) the impact of miRNAs
in β-cell identity and function through regulation of “disallowed”
genes and (2) the role that miRNAs may play in loss of β-cell
identity in situations of cellular stress, including diabetes, obesity,
pregnancy, or aging.
MiRNAs AND DISALLOWED GENES
The normal secretory function of the β-cell requires the activation
of several genes which are expressed in none or only a
few other tissues. For example, the low affinity hexokinase,
glucokinase (hexokinse type IV) is preferentially expressed
in liver and β-cells and operates as a physiological glucose
sensor thanks to its unique kinetic properties, different from
those of hexokinases present in other tissues (Iynedjian, 2009).
Conversely, several genes that serve a “housekeeping” role in
most other cell types are poorly expressed or absent in β-cells.
The two founder members of this group of “Disallowed” genes
are the monocarboxylate transporter-1 (MCT-1/Slc16a1) and
lactate dehydrogenase A (LDHA) (Sekine et al., 1994; Zhao
et al., 2001). Previous studies have demonstrated that the low
expression of those genes is likely, on one hand, to assure
that pyruvate derived from glycolysis is preferentially directed
toward mitochondrial oxidation – reinforcing the ability of
glucose to stimulate insulin secretion- and, on the other hand,
to avoid the stimulation of insulin secretion by the pyruvate
generated by muscles during intense physical exercise (Pullen
et al., 2012). Indeed, human mutations within the SLC16A1
(MCT-1) promoter which increased its expression were found
in families suffering from exercise-induced hyperinsulinemia
(EIHI) (Otonkoski et al., 2007), revealing the importance of
the absence of this transporter from β-cell for normal insulin
secretion. Our group and others have subsequently identified
∼60 disallowed genes in the murine β-cell (Pullen et al., 2010;
Thorrez et al., 2011), 11 of which were common in both of these
studies. We have also recently demonstrated the importance of
the silencing of another member of this family, the Acyl-CoA
thioesterase 7 (Acot7) which β-cell specific overexpression lead
to glucose intolerance and impaired insulin secretion in response
to glucose (Martinez-Sanchez et al., 2016). These defects were
associated with increased ATP consumption and decreased Ca2+
fluxes and insulin secretion in transgenic islets in response to
glucose.
Interestingly, several disallowed genes have been found up-
regulated in diabetic human islets (Marselli et al., 2010; Pullen
and Rutter, 2013) and in islets from mouse models characterized
by impaired β-cell identity such as those with β-cell specific
deletion respectively of AMPK or Rfx6 (Kone et al., 2014; Piccand
et al., 2014).
As occurs for β-cell-specific gene expression, disallowed
gene repression is ensured at different levels. For example,
the promoters of several disallowed genes, including those
mentioned above, are enriched for repressor H3K27me3 histone
marks in β-cells (van Arensbergen et al., 2010). As mentioned
above, our group has recently demonstrated that miRNAs
contribute to the in vivo silencing of 6 out of the 11 disallowed
genes identified by both Pullen and Thorrez: Slc16a1, Maf,
Oat, Fcgrt, Igfbp4, and Pdgfra (Martinez-Sanchez et al., 2015).
Importantly, the up-regulation of the latter genes correlated with
the loss of the secretory ability of the Dicer-depleted islets but
preceded β-cell apoptosis, suggesting a role for gene disallowance
in the former. Importantly, we demonstrated that five of those
six disallowed genes (Slc16a1, Maf, Oat, Fcgrt, and Pdgfra) are
directly targeted by miRNAs. As discussed below, the identity of
those miRNAs has only been partially unraveled so far (Figure 3).
Pullen et al. (2011) have also demonstrated in vitro that miR-
29b and miR-29c repress Slc16a1. Although, this gene is regulated
by miR-124 in medulloblastomas (Li et al., 2009), miR-124 is not
expressed at significant levels in mouse islets, at least in young
adults, and is thus unlikely to impact Slc16a1 expression in β-cells
at this developmental stage (Pullen et al., 2011). More recently,
Liang et al. (2015) showed that miR-495 targets Slc16a1 in human
embryonic stem cell (hESC) derived pancreatic endoderm that
improved T2D symptoms upon transplantation in a murine
model for T2D.
Maf is an activator of glucagon expression in α-cells that is
repressed by miR-125b, miR-182 and miR-200c in MIN6 cells
(Klein et al., 2013). Interestingly, the expression of Maf and its
regulatory miRNAs is negatively correlated in β- and α-cells.
A fascinating hypothesis is that alteration of those miRNAs,
and others targeting this gene, contributes to β- to α-cell trans-
differentiation.
Pdgfra is an important regulator of β-cell proliferation in
mouse and humans as its repression contributes to limit the
proliferative capacity of the adult β-cell (Chen et al., 2011). Pdgfra
3′ UTR is unusually long, characteristic of mRNAs subjected
to tight post-transcriptional regulation and is predicted to be
targeted by more than 50 conserved miRNAs1. Indeed, Pdgfra
is an experimentally validated target for miR-34a in pulmonary
artery smooth muscle and colon cancer cells and glioblastoma
1www.targetscan.org
Frontiers in Genetics | www.frontiersin.org 6 January 2017 | Volume 7 | Article 226
fgene-07-00226 January 9, 2017 Time: 11:30 # 7
Martinez-Sanchez et al. MiRNAs in β-Cell Identity
FIGURE 2 | Regulation of β-cell identity by miR-7 (A) miR-7 gene circuits prevailing in pancreatic β-cells. Functional analyses revealed that miR-7 controls three
essential axes maintaining the identity of pancreatic β-cells: (1) Insulin gene transcription (left); (2) Insulin secretion (middle); and (3) β-cell proliferation (right). miR-7
represses Pax6 and Gata6 mRNAs, two transcription factors modulating insulin gene transcription. miR-7 also controls the expression of PKCβ, a Ser/Thr protein
kinase activated following Ca2+ release, and SNCα and CSPα, two components of the exocytosis machinery modulating SNARE activity and the late step of insulin
granule fusion with the plasma membrane. Finally, evidence indicate that miR-7 is a negative regulator of β-cell proliferation by repressing the expression of core
components of the mTOR signaling pathways including p70S6K, eIF4e, Mapkap1, and Mknk1/2. By concomitantly repressing targets of these three axes, miR-7
couples rates in insulin transcription and secretion to β-cell proliferation. ∗Denotes a direct target of miR-7. (B) Regulation of miR-7 expression mediates the
functional adaptation of β-cells to metabolic stress. Schematic illustrating the progressive changes in glucose (blue) and insulin (green) concentrations as well as in
islet miR-7 expression (red) during the physio-pathological progression of type 2 diabetes. Fluctuations of these parameters are supported from data obtained with
miR-7 mutants mice, mouse models of obesity and diabetes, as well as observations made in primary human islets and obese and diabetic patients. Data source:
Esguerra et al. (2011), Kredo-Russo et al. (2012), Wang et al. (2013a), Latreille et al. (2014). See the main text for further details.
(Genovese et al., 2012; Li C. et al., 2015; Wang P. et al., 2016),
miR-130a during mesodermal specification (Singh et al., 2015),
miR-146b-5p in blood cells and hepatocellular carcinoma (Zhu
et al., 2013; Zhai et al., 2014) and miR-140 during palatogenesis
(Eberhart et al., 2008). Moreover, the Regazzi laboratory, in
collaboration with ourselves, has very recently demonstrated that
miR-34a targets Pdgfra in rat islet cells (Tugay et al., 2016).
As discuss below, miR-34a expression increases with age in rat
and human islets and might thus be involved in the age-related
decline in β-cell proliferation through its target Pdgfra (Tugay
et al., 2016). Interestingly, both miR-34a and miR-146 may
impact β-cell apoptosis (Nesca et al., 2013) and miR-146b has also
been implicated in the effect of cytokines on pancreatic β-cells
(Roggli et al., 2010). Seyhan et al. (2016) found that both miR-34a
and miR-146a are up-regulated in the circulation of patients with
various forms of diabetes in comparison with healthy controls,
establishing a link between those miRNAs and the development
of the disease.
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FIGURE 3 | MicroRNA (MiRNA)-mediated regulation of “Disallowed” genes in β-cells. Disallowed genes are represented in red. The red crosses indicate
pathways that are normally forbidden in β-cells thanks to the poor expression of the associated disallowed genes. MiRNAs regulating each disallowed gene are
presented in boxes, in dark red (for validated miRNA-disallowed gene interactions) or black (for predicted targeting miRNAs), see main text. Glu, glucose; Pyr,
pyruvate; Lac, lactate; Glut, glutamante; Orn, ornitine; PolII, RNA polymerase II; Mito, mitochondria. Data source: Pullen et al. (2011), Klein et al. (2013), Liang et al.
(2015), Martinez-Sanchez et al. (2015), Tugay et al. (2016). See the main text for further details.
Oat (Ornithine aminotransferase) converts arginine and
ornithine into glutamate, an intracellular second messenger
involved in the coupling of glucose metabolism and insulin
secretion. The Oat 3′ UTR is fairly short (∼750 nt), but
contains predicted binding sites for several miRNAs, including
miR-200b/c, a miRNA family that has been involved in the
development of T2D (Belgardt et al., 2015). Nevertheless, to the
best of our knowledge, experimental studies to identify miRNAs
targeting Oat have not been performed so far.
A more detailed discussion of the function of these and other
disallowed genes and their impact on β-cell identity is provided
by Pullen and Rutter elsewhere in this issue.
MiRNAs and β-CELL RESPONSES TO
STRESS
A miRNA typically targets several genes simultaneously whereas
a given gene is generally targeted by various miRNAs at the same
time. The main “duty” of miRNAs is thus to confer robustness
and flexibility to cellular systems, buffering gene expression and
enabling cells to maintain and transmit their states to daughter
cells (Ebert and Sharp, 2012; Siciliano et al., 2013). It is not,
therefore, surprising that loss of miRNA function in vivo rarely
results in strong phenotypes under normal conditions, but that
these become evident under stress situations. MiRNAs and stress
signals can form intricate networks which might diminish or
potentiate the stress signals, or even affect the threshold at which
these are activated (Ebert and Sharp, 2012; Siciliano et al., 2013).
Throughout life, the β-cell is exposed to physiological
stresses such as obesity (which may result in elevated levels
of circulating fatty acids, pro-inflammatory cytokines, etc.,
as well as to hyperglycemia as β-cell function begins to
be impaired), pregnancy, aging, growth, or genetic insulin
resistance that might lead to endoplasmic reticulum (ER) stress,
metabolic and oxidative stress, amyloid toxicity, inflammation
or loss of cellular integrity. Failure of the β-cell to adequately
respond to stress results in loss of β-cell function and mass
(see above) and the extent to which loss of β-cell identity
contributes to these effects is currently a matter of active
debate (Butler and Dhawan, 2015; Rutter et al., 2015; Butler
et al., 2016; Jeffery and Harries, 2016; Md Moin et al.,
2016).
Given the central role of miRNAs in handling cellular
stress and in stabilizing β-cell fate during development, it
is anticipated that these small molecules may be involved
in the response of the β-cell to stress. Researchers have
therefore made a considerable effort to identify miRNAs
whose expression is altered in β-cells by various types of
stress and disease. Hence, variation in miRNA expression
has been observed, for example, during compensatory β-cell
expansion, during pregnancy and in obesity (Jacovetti et al.,
2012; Tattikota et al., 2014), in islets from NOD mice, a
model for cytokine-induced T1D (Roggli et al., 2012), islets
from T2D murine models such as the Goto-kakizaki (GK)
rat or db/db mice (Esguerra et al., 2011; Nesca et al.,
2013), in human type 2 diabetic islets (Kameswaran et al.,
2014; Locke et al., 2014), and during aging (Tugay et al.,
2016).
Below, we discuss a potential role for miRNAs in maintaining
β-cell identity and function during the most common stress
situations that affect β-cells.
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Hyperglycemia, Hyperlipidaemia, and
Diabetes
Central to the development of overt diabetes is the fact that
high blood glucose negatively affects pancreatic β-cell function,
producing a vicious circle that eventually results in complete
β-cell failure (Jonas et al., 1999). The pathways underlying the
deleterious effects of glucose on β-cells are far from being
completely understood. Loss of the differentiated state of β-cells
has been proposed as a major contributor to this failure (Jonas
et al., 1999; Talchai et al., 2012; Jeffery and Harries, 2016). As
such, glucose not only regulates insulin secretion, but also insulin
mRNA transcription, stability and translation and it exerts a
strong and long-lasting effect on gene expression (Schuit et al.,
2002; Ren et al., 2007).
Early studies aimed to clarify the impact of glucose on the
β-cell miRNome. Tang et al. (2009) used an array platform in
a mouse β-cell line (MIN6) and found that the expression of
dozens of miRNAs changed when these cells were cultured at
various glucose concentrations for as little as 16 h. Of the miRNAs
affected, only miR-124a, miR-107, miR-30a,d (up-regulated), and
miR-690 (down-regulated) were further validated by RT-qPCR
(Tang et al., 2009). MiR-30d stimulates insulin mRNA expression
and is down-regulated in db/db mouse islets (Zhao et al., 2012).
Suggesting a role as a positive regulator of β-cell identity, miR-30d
indirectly promoted MafA expression, although it did not affect
the expression of other transcriptional regulators such as Pdx1
and NeuroD (Tang et al., 2009; Zhao et al., 2012). Although, it is
believed that the effect of miR-30d on MafA is at least partially
mediated by its direct target MAP4K4 (Zhao et al., 2012), other
miR-30d targets in β-cells are as yet unidentified.
Studies focused in specific miRNAs have identified several
other miRNAs that are regulated by glucose. For example, miR-
375 is down-regulated in a rat insulinoma cell line (INS1)
cultured at high glucose concentration during 48 h (El Ouaamari
et al., 2008). Surprisingly, miR-375 expression is rapidly down-
regulated in rat islets exposed to high glucose but strongly up-
regulated following a longer period of incubation (El Ouaamari
et al., 2008). MiR-375 expression is also reduced in diabetic
GK rat islets (El Ouaamari et al., 2008). A similar pattern
has been observed for miR-15a, a miRNA that promotes
insulin biosynthesis by targeting uncoupling protein-2 (UCP-2)
(Sun et al., 2011). MiR-15a is up-regulated in mouse islets
exposed to high glucose for 1 h but down-regulated by a
longer incubation with the sugar. This plasticity may reflect the
dual role of glucose in β-cell function: glucose is required for
adequate insulin secretion whereas chronic exposure of β-cells
to high glucose concentrations eventually results in β-cell failure
(glucotoxicity).
Additional examples are miR-184, whose role in the β-cell
will be discussed below, negatively regulated by high glucose in
mouse and Drosophila (Tattikota et al., 2015) and miR-133a and
miR-146, up- and down-regulated by glucose in human islets,
respectively (Fred et al., 2010). The latter miRNA, as well as
miR-34a, are also modulated by other stressors such as cytokines
(Lovis et al., 2008b; Fred et al., 2010) and are up-regulated in
diabetic db/db mouse islets (Lovis et al., 2008b). Whereas miR-
133a induction mediated the hyperglycemia-induced repression
of insulin biosynthesis (Fred et al., 2010) and could therefore
be involved in β-cell differentiation, miR-34a and miR-146 are
probably implicated in β-cell survival (Lovis et al., 2008b).
Further supporting a role for miRNAs in mediating the effects
of nutrients on β-cell differentiation and function, Regazzi et
al. have recently demonstrated that the expression of several
miRNAs such as miR-29b, miR-17 and miR-25, changes during
the post-natal β-cell maturation that occurs at weaning (Jacovetti
et al., 2015). Nutrient changes associated with weaning have been
demonstrated to trigger complete β-cell maturation, at least in
mice, required for adequate β-cell secretion and compensatory
proliferation (Stolovich-Rain et al., 2015).
Considerable efforts have been directed toward the
identification of miRNAs altered in diabetic human islets.
Using RT-qPCR-based arrays, Locke et al. (2014) detected an
increase in the expression of miR-187 and miR-345 in T2D islets
versus control. In this study we demonstrated that miR-187
can control glucose stimulated insulin secretion in INS1 cells,
although an effect in beta-cell identity remains to be evaluated.
Two years ago, Kaestner’s group compared the expression
of miRNAs between islets from diabetic and healthy donors
using cutting-edge deep sequencing technology (Kameswaran
et al., 2014). As well as confirming the large changes in miR-187
demonstrated by Locke et al. (2014), this approach allowed the
authors to identify a miRNA cluster (DLK1-MEG3) dramatically
down-regulated in diabetic islets. DLK1-MEG3, one of the largest
human miRNA clusters, is a maternally imprinted locus at human
chromosome 14q32 that contains several coding-genes, snoRNAs
and 54 miRNAs (Benetatos et al., 2012). Several of those miRNAs
(13) were down-regulated in the T2D islets (Kameswaran et al.,
2014). The miRNAs from the DLK1-MEG3 cluster were on
average expressed at much higher levels in sorted beta- than in
alpha-cells, probably due to a loss of the repressive H3K27me3
marks in the promoter of this locus (Kameswaran et al.,
2014). Moreover, islets from T2D donors contained increased
DNA methylation in a differentially methylated region (DMR)
overlapping with the MEG3 promoter which is responsible of
the maternal imprinting (Kameswaran et al., 2014). Using HITS-
CLIP (High-throughput Sequencing following Crosslinking and
Immunoprecipitation) with Argonaute 2 (Ago2), an essential
component of miRISC, the same authors isolated the human islet
miRNA targetome and identified over 12,000 mRNA targets for
miRNAs as well as more than 450 miRNAs associated in miRISC.
They also found that miRNAs target islet mRNAs through not
only the 3′ UTR but also the CDS and, to a less extent, the 5′ UTR.
Although, they didn’t experimentally identify all the mRNAs
targeted by the miRNAs altered in T2D islets, they confirmed that
IAPP (islet amyloid polypeptide), known to trigger β-cell death
and dysfunction in T2D (Montane et al., 2012), is a target for
miR-376a and miR-342.
Kameswaran et al. (2014) also made the important discovery
that a small proportion of chimeric reads mapped simultaneously
to a miRNA and an mRNA, establishing miRNA-mRNA pairs.
The latter allowed them to identify other targets for miRNAs
of the DKL1-MEG3 locus. For example, they demonstrated
that miR-495 targets the apoptosis-related gene TPN53INP1.
TPN53INP1 is the nearest gene to a SNPs associated with T2D
Frontiers in Genetics | www.frontiersin.org 9 January 2017 | Volume 7 | Article 226
fgene-07-00226 January 9, 2017 Time: 11:30 # 10
Martinez-Sanchez et al. MiRNAs in β-Cell Identity
(Voight et al., 2010), and global inactivation in mice leads
to glucose intolerance reflecting impaired insulin sensitivity
which is uncompensated by changes in β-cell function or
mass (Seillier et al., 2015). Gene ontology analysis of the
mRNAs identified in miRISC showed enrichment in biological
processes such as “protein localization and transport,” “protein
ubiquitination,” “regulation of cell death,” and “phosphorous
metabolic processes.” It would be of great interest to interrogate
these data for genes characteristic of β-cell differentiation and de-
differentiation, including transcription factors, neuronal genes,
or those characteristic of other endocrine cells or precursors.
Pregnancy, Obesity, and β-Cell
Compensation
During obesity and pregnancy, a decrease in insulin sensitivity
raises the body’s need for insulin. In both cases, β-cells
need to compensate for a higher insulin requirement that
otherwise would lead to gestational and/or T2D. Compensation
is characterized by an increase in the number and the secretory
activity of the β-cells (Singh, 2016).
Work by Regazzi and co-workers group has greatly
contributed to our understanding of the role of miRNAs
during these compensatory processes. Using microarrays and
RT-qPCR this group identified several rat islet miRNAs whose
expression was altered during gestation (Jacovetti et al., 2012).
Of those, miR-218, miR-338-3p, and miR-874 were up-regulated,
whereas the expression of miR-144 and miR-451 was reduced.
Of note, the targets of these miRNAs are diverse: miR-338
affected mouse islet cell proliferation (although its effects were
not recapitulated in humans) whereas miR-338 and miR-451
were involved in the detriment effects of cytokines and palmitate
on the cells (Jacovetti et al., 2012). Interestingly, Talchai reported
that multiparous mice with FoxO1 ablation displayed increased
number of β-cells that have loss insulin expression, and thus
their identity (Talchai et al., 2012). A proportion of these cells
retained expression of transactivators of insulin gene expression
(e.g., Pdx1 and MafA), but concomitantly expressed glucagon,
somatostatin, or pancreatic polypeptide. Further studies are
necessary to fully understand whether the above miRNAs are
required for normal compensatory responses or whether changes
in their expression occur as a consequence of metabolic stress.
It is also a strong possibility that the miRNAs involved in
β-cell compensatory response differ depending on the type of
stress that stimulates compensation. For example, early studies
by Poy et al. (2009) demonstrated that miR-375 is required
for β-cell compensation in leptin-deficient mice, whereas the
study by Jacovetti et al. (2012) did not find differences in the
expression of this miRNA during pregnancy. Another example
is miR-184, whose expression is strongly decreased in mouse
models of obesity and insulin resistance as well as in human
T2D islets (Tattikota et al., 2014) but not during pregnancy
(Jacovetti et al., 2012). The relevance of miR-184 silencing during
β-cell compensation has mainly been attributed to one of its
targets, Ago2, an essential mediator of miRNA function and
the β-cell compensatory proliferation (Tattikota et al., 2014).
Another important target of miR-184 is the glutamate transporter
Slc25a22, which plays a major role in the effect of miR-184 in
insulin secretion and mitochondrial function (Morita et al., 2013;
Tattikota et al., 2015). Even though miR-184 overexpression in
MIN6 cells did not exert a strong impact on gene expression,
a certain degree of de-differentiation was hinted at by the
up-regulation of Ngn3 and Ppy and the down-regulation of
MafA (Tattikota et al., 2015). Additional studies are required to
determine if this de-differentiation occurs upon stress conditions
in vivo and its impact in β-cell function.
Aging
T2D is an age-related disease, and aging represents a major risk
factor (De Tata, 2014). Age appears to contribute to increased
insulin resistance, impaired β-cell insulin secretion (but see
below), β-cell senescence and reduced β-cell proliferation (De
Tata, 2014). Nevertheless, the extent and causes of these defects
remain contested. Moreover, many of the mechanisms that
contribute to the impairment of β-cell function and survival with
age have been established only in murine models. However, it has
recently become apparent that these might not be extrapolated
directly to humans. For example, whereas in both rodents
and humans β-cell proliferative capacity decreases with age
(Teta et al., 2005; Maedler et al., 2006; Parnaud et al., 2008),
proliferation of β-cells is almost undetectable after adulthood
in man (Perl et al., 2010), at least outside of pregnancy (Butler
et al., 2010). The impact of age in the secretory capacity of
the β-cell is also unclear in both rodents and humans (De
Tata, 2014). Nonetheless, the expression of genes essential for
maintenance of the β-cell differentiated status, such as FOXO1
and PDX1 decreases with age in both murine and human islets,
respectively (Kitamura et al., 2002; Maedler et al., 2006). This
suggests that some loss of β-cell identity occurs with age. In
fact, as with multiple pregnancy, aging mice with β-cell-specific
Foxo1 inactivation display a significantly higher number of β-cells
that have loss insulin expression and adopted an α, δ- or PP-cell
identity (Talchai et al., 2012).
To shed light into the role of miRNAs during aging, Tugay
et al. (2016) used microarrays to profile miRNAs expressed in
3- and 12-month rat islets. This study allowed the authors to
demonstrate that the expression of as many as 69 miRNAs was
altered with age. Of these, miR-124a, miR-383, miR-34a (up-
regulated) and miR-181a and miR-383 (down-regulated) were
subsequently confirmed by RT-qPCR. MiR-34a had previously
been associated with aging in other tissues and organisms (Li
et al., 2011; Liu et al., 2012) and demonstrated to control
insulin secretion and islet cell survival (Roggli et al., 2010).
Suggesting a conserved regulatory mechanism in humans, miR-
34a expression also correlated with age of human islet donors
(Tugay et al., 2016). Interestingly, modulation of miR-34a, miR-
383, and miR-130b strongly impact the response to different
age-related apoptotic stimuli (Gunasekaran and Gannon, 2011;
Tugay et al., 2016). Intriguingly, Tugay et al. (2016) found that
12-month old islets, although fully functional, failed to proliferate
in response to mitotic stimuli such as exendin-4, PDGF or
prolactin and demonstrated that miR-181a down-regulation
or miR-34a up-regulation inhibited exendin-4 or PDGF-AA
-stimulated proliferation. Pathway analysis of protein-coding
genes concurrently affected by age identified, between many
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others, enrichment in pathways involved in the establishment,
maintenance or loss of β-cell identity including MAPK, HIF-1
and FoxO signaling, as well as several neuronal-related pathways
(Tugay et al., 2016).
Although, a link between age-dependent miRNAs and these
pathways remains to be investigated, this study did allow us to
demonstrate that miR-34a targets the disallowed gene PDGFRA,
whose expression is reduced in aged rat islets, limiting their
proliferation (Chen et al., 2011; Tugay et al., 2016).
PERSPECTIVES FOR FUTURE STUDY
Mechanisms Underlying Regulation of
miRNA Expression in β-Cells
Similar to protein-coding genes, miRNAs are susceptible to
epigenetic and transcriptional regulation. Although the field of
β-cell epigenetics is still in its infancy, examples in which miRNA
expression is epigenetically controlled during development
and disease have already started to emerge: as mentioned
above, miRNAs from the DLK1-MEG3 cluster are regulated by
differential DNA methylation around the MEG3 promoter in
T2D islets (Kameswaran et al., 2014). Similarly, others (Hall
et al., 2014) found that lower methylation of two miRNAs in
the chromosome X, miR-660 and miR-532 correlated with higher
expression levels in female versus male pancreatic islets.
In general, expression of pri-miRNAs is controlled by the
same type of promoters as protein-coding genes, and involves
the presence of distal enhancers. Considerable experimental
and computational efforts have been directed toward the
identification of pri-miRNA transcription start sites (TTS)
(Marson et al., 2008; Chien et al., 2011; Nieto et al., 2012;
Georgakilas et al., 2014). Nevertheless, TSSs can be located
up to 100s of kilobases away from the corresponding mature
miRNA which adds to the fact that pri-miRNAs are short-lived
due to their rapid processing into mature miRNAs (Ha and
Kim, 2014). Thus, TSSs haven’t been accurately identified for
most miRNAs, neither have been the sequences responsible for
their transcriptional regulation. Nonetheless, specific examples
demonstrate that transcription factors, as well as being target of
miRNAs themselves, control miRNA expression in islets. Thus,
binding of Pdx-1 and NeuroD1 to the miR-375 locus has been
suggested to play a critical role during β-cell maturation (Keller
et al., 2007).
Micro RNA expression is subjected to additional levels
of control throughout the multi-stepped processing of their
primary transcripts. As recently reviewed by Connerty et al.
(2015), several RNA-binding proteins (RBPs) drive miRNA
maturation from their precursors. Thus, DROSHA and DGCR8
are responsible for pri-miRNA cleavage into the intermediate
∼80 nt pre-miRNA in the nucleus, which is further processed
by DICER and other co-factors such as PACT and TRBP in
the cytosol. The important members of miRISC, argonaute
proteins, not only are essential for miRNA-mediated target
repression but have also been demonstrated to affect miRNA
maturation in mammals (Diederichs and Haber, 2007; Czech
and Hannon, 2011). In human islets, DICER is controlled by
glucose (Schrimpe-Rutledge et al., 2012), whereas AGO2 has
been proposed as an important player in β-cell compensatory
expansion (Tattikota et al., 2014). Although, to the best of
our knowledge, the regulatory mechanisms controlling miRNA-
processing in the β-cell have not so far been investigated, several
miRNAs with a role in β-cell identity are regulated at the
pri/pre-miRNA processing level in other cell types. Examples
are the already mentioned miR-7 (see above), miR-34a (Doridot
et al., 2014; Herbert et al., 2014) or miR-146a (Srivastava et al.,
2015).
Likewise, miRNA stability can be modulated in response
to specific cellular stimuli or in a context-specific manner.
MiRNAs are in general very stable, with an average half-life
of ∼120 h (Gantier et al., 2011) but they can be subject to
post-transcriptional modifications such as 3′-adenylation, 3′-
uridylation and 2′-O-methylation, that may impact miRNA
stability (Towler et al., 2015). Moreover, RBPS can also alter
miRNA half-life (Diederichs and Haber, 2007; Towler et al.,
2015), which can be further affected by other non-coding RNAs
acting as miRNA sponges (Thomson and Dinger, 2016). As
mentioned above, miR-7 represents an example of this type of
regulation in β-cells. MiR-7 can be sequestered by a circular RNA
acting as a miR-7 sponge (Xu et al., 2015). Whether and how
miRNAs contribute to the roles in controlling β-cell identity of
nutrient-sensing systems such as AMP-activated protein kinase
(AMPK)- (Sun et al., 2010; Kone et al., 2014) and Per-Arnt-Sim
(PASK)- (da Silva Xavier et al., 2004; Semplici et al., 2016) is also
an intriguing area for future research.
Last but not least, RBPs can also modulate the efficacy
of miRNA repression by affecting the structure of the target
mRNA or the efficiency of miRISC recruitment (Kedde et al.,
2007; Gulyaeva and Kushlinskiy, 2016). Accordingly, differential
miRNA-mediated regulation in response to stress or metabolic
signals can potentially occur without observable changes in
miRNA expression.
Whereas, there is little doubt that epigenetic and
transcriptional regulation of miRNA expression plays a
central role in the establishment, maintenance and loss of
cellular identity, studies on the mechanisms underlying
miRNA processing, post-transcriptional modifications, stability
and efficacy have only started to emerge. Future research
tackling these questions will provide essential insights into the
mechanisms governing miRNA function in the β-cell.
MiRNAs and Generation of Functional
β-Cells for Replacement Therapy in
Diabetes
In recent years, several strategies have been envisaged to improve
pancreatic islet function and identity in both Type 1 diabetes
(T1D) and T2D. These were mainly based on (1) replacement
of individual β-cells through human islet transplantation (2)
stimulation of existing β -cell proliferation (3) prevention
of β -cell death (i.e., blockade of apoptosis) (4) large-scale
production of β-cells from multipotent progenitors and (5)
expansion human of islet cells. Due to the low efficacy of islet
transplantation mostly attributed to the rejection of transplants
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from hosts, some researchers turned their attention to the
identification of pharmacological agents that stimulated β-cell
proliferation. Whereas many groups identified ligands that
increased β-cell mass in mice, very few of these showed beneficial
effects in humans (Lovis et al., 2008a). One recently identified
molecule that may have a promising future is SerpinB1, a liver-
derived secretory protein, which enhances β-cell proliferation
in zebrafish and mice and also stimulates the proliferation of
human islets (Lovis et al., 2008b). Furthermore, TGFβ inhibitors
were recently found to reverse the dedifferentiation process of
expanded mouse (Blum et al., 2014) and human β-cells (Toren-
Haritan and Efrat, 2015), revealing a degree of plasticity of
dedifferentiated β-cells which could potentially be targeted by
drugs to improve β-cell identity.
A considerable body of research into the intricate mechanisms
governing β-cell differentiation during development, and recent
advancements on somatic transfer and cell reprograming, have
paved the way to the production of β-cells from hESC and
induced pluripotent stem (iPSC) cells (Plaisance et al., 2006;
Liao et al., 2013; Park et al., 2013). Whereas production of
β-cells en masse following the differentiation of hESC and iPSCs
may allow a more personalized therapy for diabetes, many
challenges are in front of us before stem cell-based diabetes
therapies can be widely used by patients with diabetes (reviewed
in Quiskamp et al., 2015). Whether, such strategies could be used
in combination of drugs that normalize the identity of existing
β-cells in diabetic patients still needs to be determined. Below we
present recent advances describing how manipulation of miRNAs
expression may act on β-cell identity and our ability to generate
functional β-cells from multipotent progenitors and dissociated
adult human islet cells.
β-Cells from hESCs
In order to better understand the molecular components involved
in the differentiation of pluripotent cells into insulin-producing
cells, several groups have profiled the expression of miRNAs
during differentiation of hESC using protocols established in
recent years (D’Amour et al., 2005; Kroon et al., 2008; Nostro
et al., 2011). These studies revealed that two of the most highly
expressed miRNAs in adult liver and pancreas, namely miR-122
and miR-375, are also amongst the most highly induced miRNAs
during the differentiation of ESCs into definitive endoderm
(Tzur et al., 2008; Hinton et al., 2010; Kim et al., 2011; Francis
et al., 2015). MiR-30d and miR-200a are also induced during the
differentiation of hESC into definitive endoderm whereas miR-
151a-5p and miR-151-a-3p were up-regulated in differentiated
hESCs (Migliorini et al., 2014; Francis et al., 2015). Chen
et al. group have shown that miR-186, -199a, and -339 are
found at higher levels in islet-like insulin-positive cell clusters
derived from the differentiation of hESC (Joglekar et al., 2009b).
Interestingly, acquisition of insulin expression in differentiated
hESCs correlates with increased expression of miR-375 (Liao
et al., 2013; Wei et al., 2013) and miR-375 overexpression is
sufficient to promote pancreatic endocrine differentiation from
hESCs in the absence of any extrinsic inducers (Jopling et al.,
2005). In fact, overexpression of miR-375 of mesenchymal stem
cells obtained from either human bone marrow or human
placenta can also redirect them into functional insulin-expressing
cells (Bazzini et al., 2012; Shaer et al., 2014b). These studies
illustrate the crucial role of miR-375 in governing for the
initiation phase of ESC differentiation and acquisition of insulin
expression in β-cell precursors.
β-Cells from iPSCs
Induced pluripotent stem cells generated from the
reprogramming of skin fibroblasts (Maekawa et al., 2011)
have also been widely used for the generation of endoderm and
insulin-producing cells. Porciuncula et al. (2013) have measured
the expression of miRNAs during induction of iPSCs into
endoderm and identified 13 up-regulated miRNAs including
miR-18a -103, -206, -302a/c and the islet-enriched miR-141
and miR-200c. Conversely, reprogramming of skin fibroblasts
isolated from T1D patients in iPSCs is accompanied with the
induction of pancreas-enriched miR-7, miR-9, and miR-375
compared to parental fibroblasts, strengthening the role of these
miRNAs in human pancreatic progenitors (Liu et al., 2014).
Together, these studies suggest that modulation of miRNAs levels
may affect the ability of multipotent stem cells to differentiate
into insulin-positive cells. Conversely, overexpression of miR-
186 and miR-375 by chemical transfection of human iPSCs
promoted islet-like cell cluster formation associated with the
induction of markers found in endocrine progenitors (Ngn3)
and mature β-cells (Insulin, Pdx1, Pax4/6, Nkx6-1, Glut2, and
Kir6.2) (Shaer et al., 2014a). Interestingly, the same group
obtained similar results when miR-7 was overexpressed (Shaer
et al., 2016). Virus-mediated overexpression of miR-375 in
human skin fibroblast-derived iPSCs is sufficient to trigger
their differentiation into insulin-expressing cells and allow
glucose-dependent insulin secretion in vitro (Lahmy et al., 2014).
Finally, hESCs overexpressing miR-410, miR-495, and miR-590
that have subsequently been subjected to differentiation into
endoderm can improved glycemic control when transplanted
in mouse models of gestational or T2D diabetes (Chen et al.,
2015; Liang et al., 2015; Mi et al., 2015). Interestingly, Ldha and
Mct1/Slc16a1, two disallowed genes in β-cells, are repressed by
these miRNAs in hESCs (Chen et al., 2015; Liang et al., 2015; Mi
et al., 2015), demonstrating that miRNA-mediated regulation
of disallowed genes is also of functional importance during the
differentiation of pluripotent cells into β-cells. Together these
studies reveal the great therapeutic potential of miRNAs in
stem-cell-based approaches for treatment of diabetes.
β-Cells from Expansion of Human Islets
One approach to counteract the shortage of islet donation
relies on the expansion of dissociated human β-cells which is,
however, limited by the low proliferation rate of these cells
and by the loss of β-cell phenotype (i.e., de-differentiation) that
occurs during their in vitro propagation reviewed in (Efrat,
2008). Growth signals were found to trigger an epithelial-
mesenchymal transition (EMT) process in those cells which
correlated with the activation of TGFβ (Toren-Haritan and
Efrat, 2015), Notch (Bar et al., 2008) and Wnt (Lenz et al.,
2014) signaling pathways. Nathan et al. (2015) analyzed changes
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in miRNA expression following expansion of human adult
β-cells undergoing such de-differentiation process and found
that expression of miR-375, miR-192, miR-204, miR-215 and
the miR-200 and miR-30 families is down-regulated compared
to undifferentiated control β-cells. Importantly, overexpression
of miR-375 induced the expression of several key transcription
factors such as PDX1, MAFA, NKX6.1 and PAX4, indicative
of re-differentiation. Repression of the PDK1-AKT pathway by
miR-375 mediated this re-differentiation process at least to some
extent (Nathan et al., 2015). Whether restoring the expression of
other miRNAs altered in de-differentiated β-cells promotes their
re-differentiation remains to be evaluated, but the above studies
suggest that modulation of miRNA expression in dissociated
human β-cells may prevent their dedifferentiation in culture. As
such, this strategy may provide a new therapeutic avenue for the
generation of functional insulin-producing cells.
MiRNAs and β-Cell Heterogeneity
Although, several lines of evidence support a role for miRNAs
in regulating the identity of pancreatic β-cells, these observations
need to be interpreted with caution especially in light of recent
studies demonstrating a high degree of heterogeneity between
individual β-cells. The functional diversity of individual β-cells
has been suspected for many years (Salomon and Meda, 1986;
Van Schravendijk et al., 1990), but the functional significance of
these differences, or the possibility that certain cells may play a
pacemaker role, has been difficult to assess. Johnston et al. (2016)
used a combination of high speed Ca2+ imaging (Hodson et al.,
2013) and optogenetic inactivation to demonstrate the existence
of “hubs” or “pacemaker” β-cells that impose synchronicity on
other “follower” cells in mouse islets. These cellular hubs display
a distinct expression profile to follower cells that is partly shared
with immature β-cells and associated with low insulin, Nkx6-1
and Pdx1 expression, but high Gck levels.
Whilst the study by Johnston et al. (2016) did not analyze
the transcriptional profile of “hub” or “follower” cells in depth,
others have recently showed that subpopulations of β-cells exist
within human islets and display a distinct genetic signature with
a specific subtype over-represented in diabetes (Bader et al., 2016;
Dorrell et al., 2016). Indeed, single cell RNA sequencing (RNA-
Seq) has extended these findings to demonstrate heterogeneity at
the level of individual human β-cell transcriptomes (Segerstolpe
et al., 2016). How and when such heterogeneity is created during
development still remains to be fully elucidated, and the role of
miRNAs unknown. Of note, heterogeneity was observed several
years ago in primary and distal tumors found at secondary sites
as well as within cells of a tumor (Heppner, 1984). Interestingly,
an intra-colorectal tumor gradient has been found for miR-
375 and miR-200c, two miRNAs enriched in pancreatic β-cells
(Jepsen et al., 2016). Given that several miRNAs modulate the
identity of β-cells through repression of a plethora of pancreatic
transcriptional regulators and enzymes required for the function
of the mature cell (see above), it is possible that the differential
expression of miRNAs plays a role in establishing cellular
diversity within islets. It remains, however, to be investigated
whether discrete subpopulations of pancreatic β-cells display
distinct miRNA gene expression profiles. Nonetheless, with the
advance of single cell RNA-Seq (Segerstolpe et al., 2016; Wang Y.J.
et al., 2016; Xin et al., 2016), we are likely soon to have answers to
these questions.
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